meningococcal polysaccharide diphtheria toxoid conjugate vaccine

(me-nin-go-kok-al poli-sak-a-ride vax-seen) ,


(trade name),


(trade name)


Therapeutic: vaccines immunizing agents
Pharmacologic: antigens
Pregnancy Category: C


Active immunization to prevent against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.


Induces production of antibodies to several pathologic serogroups of Neisseria meningitidis.

Therapeutic effects

Prevention of invasive meningococcal disease.


Absorption: Well absorbed from IM sites.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (antibody presence)

IMunknown4 wkunknown


Contraindicated in: Hypersensitivity to meningoccal polysaccharide, diphtheria toxoid or latex; Bleeding disorders (hemophilia, thrombocytopenia, concurrent anticoagulants), unless precautions are taken; Latex allergy (stopper contains latex).
Use Cautiously in: Guillain-Barré syndrome Obstetric: Use only if clearly needed (pregnancy registry participation recommended) use cautiously during lactation; Lactation: Effect on infant unknown; Pediatric: Children <9 mo (safety not established); Geriatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • irritability (Menveo) (most frequent)
  • fatigue
  • headache
  • malaise
  • syncope (Menveo)


  • diarrhea (Menveo) (most frequent)
  • anorexia
  • vomiting (Menveo)


  • pain at injection site (most frequent)
  • induration
  • redness
  • swelling


  • arthralgia


  • apnea in premature infants (Menveo)


  • anaphylaxis (menveo) (life-threatening)
  • chills
  • Guillain Barre Syndrome


Drug-Drug interaction

Immunosuppressants, antineoplastics, or radiation therapy may ↓ antibody response to and ↑ risk of adverse reactions from vaccines.May ↓ response to pneumococcal vaccine when concurrently administered



Intramuscular (Adults and Children 2–55 yr) 0.5 mL single dose
Intramuscular (Children 9–23 mo) 0.5 mL initially, then 0.5 mL 3 mo later


Intramuscular (Adults and Children 11–55 yr) 0.5 mL single dose
Intramuscular (Children 2–10 yr) 0.5 mL single dose; if patients 2–5 yr are at continued high risk for meningococcal disease, may administer another dose at 2 mo after the first dose
Intramuscular (Children 7–23 mo) 0.5 mL initially, then 0.5 mL in the second yr of life and ≥3 mo after the first dose
Intramuscular (Children 2 mo) 0.5 mL administered at 2, 4, 6, and 12 mo of age


Solution for IM injection: 0.5 mL/vial

Nursing implications

Nursing assessment

  • Review patient's immunization history for contraindications and history of sensitivity to vaccine, a similar vaccine, or latex. Stopper of Menactra vial contains dry natural latex, which may cause allergic reactions in latex-sensitive patients.
  • Monitor patient receiving Menveo for at least 15 min following injection for syncope or allergic reactions.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • Do not confuse Menactra with Menomune (meningococcal polysaccharide vaccine).
  • Record date, lot number, and manufacturer of vaccine as part of immunization record.
  • Intramuscular: Menactra: Administer as a single IM dose, preferrably in deltoid. Do not administer IV, subcutaneously, or intradermally. Inspect solution prior to administration. Do not administer if solution is discolored or contains particulate matter. Do not mix with other vaccines. If administered concurrently with other vaccines, administer a in different sites.
    • Menveo: Combine 2 vials prior to administration. Reconstitute MenA lyophilized conjugate vaccine component with MenCYW-135 liquid conjugate vaccine component by withdrawing entire contents of vial of MenCYW-135 liquid conjugate component and inject into MenA lyophilized conjugate component vial. Invert and shake vial well until the vaccine is dissolved. Withdraw 0.5 mL of reconstituted product; small amount of liquid may remain in vial following withdrawal of dose. Vaccine is clear, colorless, and free from visible foreign particles. Do not administer solutions that are discolored or contain particulate matter. Administer reconstituted vaccine immediately; vaccine is stable at room temperature for up to 8 hours. Inject in anterolateral aspect of thigh in infants or into deltoid muscle in toddlers, adolescents and adults. Do not administer intravenously, subcutaneously or intradermally.

Patient/Family Teaching

  • Inform patient of purpose of vaccine.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding prior to administration. Patients who are pregnant or become aware they were pregnant the time of the immunization, should contact health care professional or Aventis Pasteur Inc. at 1–800–822–2463.

Evaluation/Desired Outcomes

  • Immunity against invasive meningococcal disease.


A quadrivalent conjugate vaccine to prevent invasive meningococcal disease.
References in periodicals archive ?
GSK Australia today announced that MENVEO is the first combination vaccine for meningococcal strains A, C, W and Y to receive Therapeutics Goods Administration (TGA) approval for use in babies aged from two months.
Performance was driven by sales of new products including meningitis vaccines Bexsero and Menveo, and there was also strong demand for Fluarix /FluLaval.
Browse Meningococcal Vaccines Market by Meningococcal Combination Vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal Conjugate Vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); and Meningococcal Polysaccharide Vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo) and Forecast 2017-2021 at https://www.
Two meningococcal conjugate vaccines are available in the United States: Menactra, (Sanofi Pasteur), licensed for use in individuals ages 9 months to 55 years; and Menveo (GlaxoSmithKline), licensed for use in individuals ages 2 months to 55 years.
Under the deal, GSK acquired Novartis's vaccines business (excluding influenza vaccines) including the meningitis vaccines Menveo and Bexsero.
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has voted recently to recommend (13 Yes, 1 No, 1 Abstain) the meningococcal conjugate vaccine MenACWY-CRM ( Menveo, Novartis Vaccines) for use in infants and young toddlers who are at increased risk for meningococcal disease.
Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.
Menveo is now available in doctors' offices throughout the country and was also recently approved overseas in the European Union.
The vaccine, called Menveo, is likely to be used as a travel vaccine to protect people from contracting meningitis in sub-Saharan Africa.
Menveo was also approved by the US Food and Drug Administration (FDA) on the 21st of February 2010
Novartis AG received marketing clearance for its key Menveo meningococcal vaccine and got priority review for its oral treatment for multiple sclerosis (MS), underlining the promise of the Swiss group's pipeline.
GSK has a broad portfolio of approved meningococcal meningitis vaccines Bexsero as well as the tetravalent vaccine, Menveo.